cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.28902446.v2
title: Supplementary Material for: Cardiovascular Events in Lupus Nephritis; A Systematic Review and Meta-Analysis

description: Background: Systemic lupus erythematous (SLE) is known to be associated with cardiovascular events (CVE). However, the incidence of CVE has not been thoroughly investigated in lupus nephritis (LN) patients. In this meta-analysis, we aim to assess the incidence of CVE in patients with LN. 
Methods: We performed a literature search in PubMed, Scopus, and Web of Science database for studies reporting CVE (myocardial infarction (MI), heart failure, cerebrovascular accident (CVA) (i.e ischemic or hemorrhagic stroke, or transient ischemic attack), any cardiovascular or cerebrovascular-related disease or death) in patients with LN. In addition, subgroup analyses were conducted according to geographical locations and kidney disease status. We also separately reported the incidence rate of MI, CVA, and cardiovascular or cerebrovascular-related deaths, with CVE and MI risk in patients with LN.
Results: Twenty-one records, encompassing 29489 subjects, were included. The overall CVE incidence was 9% (95% confidence interval (CI): 6%-12%). Specifically, the incidence of MI (8 studies, n= 5735), CVA (9 studies, n= 6053), and mortality attributed to any cardiovascular or cerebrovascular disease (10 studies, n= 26511) were 4% (95%CI: 2%-7%), 4% (95%CI: 2%-7%), and 5% (95%CI: 3%-7%), respectively. Geographically, patients residing in Asia exhibited a lower incidence of CVE (2.3%, 95%CI: 1.6%-3.3%) compared to those residing in North America (10.1%, 95%CI: 5.7%-17.2%) and Europe (13.3%, 95%CI: 7.6%-22.4%). Patients with LN had higher risk of CVE compared to SLE subjects (hazard ratio: 1.18, 95%CI: 1.03-1.34, P= 0.014).
Conclusions: CVE occurrence among individuals with LN, is significant, and this disease entity increases CVE risk, highlighting the importance of implementing early therapeutic interventions to prevent poor outcomes.
DOI: 10.6084/m9.figshare.29069504
title: Supplementary Material for: Exclusively macular phenotype of non-syndromic MFSD8-related disease: A Case Report

description: Introduction: The purpose of this report is to highlight the clinical phenotype and imaging findings in a patient with an exclusively macular phenotype of non-syndromic MFSD8-related disease, and to provide clinical evidence for pathogenicity reclassification of a variant of uncertain significance (VUS) MFSD8 c.291G&gt;C (p.Trp97Cys). 

Case Presentation: A 47-year-old male with progressive vision loss exhibited symptoms indicative of maculopathy. These included decreased central vision, visual distortions, photophobia, poor depth perception, glare, impaired dark/light adaptation, difficulty reading, depressed multifocal ERG responses and central ellipsoid dropout on SD-OCT. Evaluation included genetic testing, segregation analysis, and a complete ophthalmic examination, including slit lamp exam, dilated fundus exam, FAF, SD-OCT, ERG and Humphrey 24-2 visual fields. A 351 gene retinal dystrophy panel revealed two variants in MFSD8, including one pathogenic variant (c.1006G&gt;C, p.Glu336Gln) and one likely pathogenic variant (c.291G&gt;C, p.Trp97Cys), confirmed to be in trans via segregation testing.

Conclusion: This case underscores the importance of genetic testing in confirming variant inheritance and describes the clinical phenotype associated with MFSD8 c.291G&gt;C (p.Trp97Cys). The variant contributes to a pathological non-syndromic phenotype when in trans with a pathogenic variant. Given the syndromic variants of MFSD8, patients with this specific variant in the homozygous or compound heterozygous state should be closely monitored for clinical manifestations associated with this condition. Genetic counseling should be recommended for affected individuals and their close relatives to provide informed guidance regarding prognosis, reproductive risks, and available support resources.
DOI: 10.6084/m9.figshare.29069504.v1
title: Supplementary Material for: Exclusively macular phenotype of non-syndromic MFSD8-related disease: A Case Report

description: Introduction: The purpose of this report is to highlight the clinical phenotype and imaging findings in a patient with an exclusively macular phenotype of non-syndromic MFSD8-related disease, and to provide clinical evidence for pathogenicity reclassification of a variant of uncertain significance (VUS) MFSD8 c.291G&gt;C (p.Trp97Cys). 

Case Presentation: A 47-year-old male with progressive vision loss exhibited symptoms indicative of maculopathy. These included decreased central vision, visual distortions, photophobia, poor depth perception, glare, impaired dark/light adaptation, difficulty reading, depressed multifocal ERG responses and central ellipsoid dropout on SD-OCT. Evaluation included genetic testing, segregation analysis, and a complete ophthalmic examination, including slit lamp exam, dilated fundus exam, FAF, SD-OCT, ERG and Humphrey 24-2 visual fields. A 351 gene retinal dystrophy panel revealed two variants in MFSD8, including one pathogenic variant (c.1006G&gt;C, p.Glu336Gln) and one likely pathogenic variant (c.291G&gt;C, p.Trp97Cys), confirmed to be in trans via segregation testing.

Conclusion: This case underscores the importance of genetic testing in confirming variant inheritance and describes the clinical phenotype associated with MFSD8 c.291G&gt;C (p.Trp97Cys). The variant contributes to a pathological non-syndromic phenotype when in trans with a pathogenic variant. Given the syndromic variants of MFSD8, patients with this specific variant in the homozygous or compound heterozygous state should be closely monitored for clinical manifestations associated with this condition. Genetic counseling should be recommended for affected individuals and their close relatives to provide informed guidance regarding prognosis, reproductive risks, and available support resources.
DOI: 10.6084/m9.figshare.29069507
title: Supplementary Material for: Effectiveness and safety of combining transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors in hepatocellular carcinoma: a meta-analysis

description: Background
Standard treatments for intermediate-stage hepatocellular carcinoma (HCC), such as transarterial chemoembolization (TACE), offer limited efficacy, necessitating the exploration of additional therapeutic strategies. Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) have shown potential to enhance HCC outcomes when combined with TACE. This meta-analysis aimed to evaluate safety and efficacy of TACE, TKIs and ICIs (TACE+T+I) combination compared to TACE with TKIs alone (TACE+T) in patients with HCC. 

Methods
A systematic search was performed in “PubMed”, “Google Scholar”, “Cochrane Library”, “Web of Science”, “Scopus”, and “Embase” databases on November 1, 2024. Studies involving patients with HCC comparing TACE+T+I versus TACE+T were included. Efficacy outcomes including objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression free survival (PFS), and adverse events, were extracted. Meta-analysis was conducted using RevMan 5.4.

Results
Seventeen studies were included for analysis. Pooled analysis showed a markedly improvement in ORR (risk ratio (RR)=1.57, 95%CI:1.36–1.80, P&lt;0.00001) and DCR (RR=1.13, 95%CI:1.06–1.20, P=0.0004) for TACE+T+I regimen over TACE+T. TACE+T+I group also showed a marked benefit in OS (hazard ratio (HR)=0.37, 95%CI:0.29–0.48, P&lt;0.0001) and PFS (HR=0.44, 95%CI:0.36–0.53, P&lt;0.0001). No differences in adverse events were detected between the two groups, indicating comparable tolerability.

Conclusions
The findings suggest that the addition of ICIs to TACE and TKI therapy offers substantial efficacy benefits without increasing toxicity for HCC patients. This combination therapy shows potential to improve DCR, ORR, PFS and OS, underscoring the value of immunotherapy in enhancing outcomes in HCC. However, further randomized trials with standardized treatment protocols are needed to confirm these results and inform clinical guidelines.
DOI: 10.6084/m9.figshare.29069510
title: Supplementary Material for: A case of postoperative pouch-vaginal fistula of ulcerative colitis successfully treated with estriol vaginal tablet

description: Introduction
Ileal pouch-vaginal fistula (PVF) is a severe complication that can occur following surgery for ulcerative colitis (UC). Most cases of PVF are managed surgically, and reports on successful clossure through conservative treatment alone are limited. We report the first documented case of PVF closure without stoma formation, successfully treated with antibiotics and estriol vaginal tablets.

Case Presentation
A 65-year-old woman was diagnosed in her 50s with total colitis-type UC. She developed steroid-dependent, refractory disease, prompting the indicationn of infliximab therapy. Howeever, infliximab failed to maintain remission, necessitating restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) followed by loop ileostomy. The postoperative course was uneventful, and the ileostomy was closed 6 months later. 
Two years after surgery, she developed fever, diarrhea, and vaginal discharge containing fecal fluid. The endoscopic evaluation identified a PVF secondary to pouchitis. She was admitted to the hospital, placed on fasting, and treated with antibiotics and estriol vaginal tablets. Endoscopy 18 days after initiating of estriol therapy revealed vaginal wall thickening and PVF closure, and she was subsequently discharged. Estriol vaginal tablet administration continued for 3 months, and no recurrence has been observed 9 years following surgery.

Conclusion
Estriol vaginal tablets may be serve as an effective conservative treatmet option for PVF followig surgery for ulcerative colitis.
DOI: 10.6084/m9.figshare.29069510.v1
title: Supplementary Material for: A case of postoperative pouch-vaginal fistula of ulcerative colitis successfully treated with estriol vaginal tablet

description: Introduction
Ileal pouch-vaginal fistula (PVF) is a severe complication that can occur following surgery for ulcerative colitis (UC). Most cases of PVF are managed surgically, and reports on successful clossure through conservative treatment alone are limited. We report the first documented case of PVF closure without stoma formation, successfully treated with antibiotics and estriol vaginal tablets.

Case Presentation
A 65-year-old woman was diagnosed in her 50s with total colitis-type UC. She developed steroid-dependent, refractory disease, prompting the indicationn of infliximab therapy. Howeever, infliximab failed to maintain remission, necessitating restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) followed by loop ileostomy. The postoperative course was uneventful, and the ileostomy was closed 6 months later. 
Two years after surgery, she developed fever, diarrhea, and vaginal discharge containing fecal fluid. The endoscopic evaluation identified a PVF secondary to pouchitis. She was admitted to the hospital, placed on fasting, and treated with antibiotics and estriol vaginal tablets. Endoscopy 18 days after initiating of estriol therapy revealed vaginal wall thickening and PVF closure, and she was subsequently discharged. Estriol vaginal tablet administration continued for 3 months, and no recurrence has been observed 9 years following surgery.

Conclusion
Estriol vaginal tablets may be serve as an effective conservative treatmet option for PVF followig surgery for ulcerative colitis.
DOI: 10.6084/m9.figshare.29069513
title: Supplementary Material for: Additional immunotherapy to standard of care for unresectable locally advanced head and neck squamous cell carcinoma: a meta-analysis

description: Background The role of immunotherapy in the treatment of locally advanced head and neck squamous cell carcinoma (LA HNSCC) remains uncertain, particularly in cases of unresectable LA HNSCC. This meta-analysis aimed to evaluate the efficacy of immunotherapy in patients with unresectable LA HNSCC through a systematic review of the existing literature. 
Methods This meta-analysis followed a registered protocol on the INPLASY platform with the registration number INPLASY202510102. We systematically collected studies that compared the combination of immunotherapy and standard of care (SOC) with SOC alone for patients with unresectable LA HNSCC. Review Manager, Stata, and R software were employed to conduct single-group rate meta-analysis, pairwise meta-analysis, and Bayesian network meta-analysis. 
Results A meta-analysis of fifteen eligible studies involving 3,055 patients revealed no significant improvement in progression-free survival (PFS) or overall survival (OS) with the addition of immunotherapy. Specifically, in patients with human papilloma-positive (HPV+) LA HNSCC, the combination of pembrolizumab and concurrent chemoradiotherapy (CCRT) resulted in 2-year PFS and OS rates of 93% and 97%, respectively. In contrast, LA HNSCC patients treated with chemoradiotherapy followed by sequential pembrolizumab exhibited 2-year PFS and OS rates of 89% and 94%, respectively. Furthermore, our study demonstrated that the combination of pembrolizumab and CCRT achieved a higher 2-year PFS rate compared to the combination of avelumab and CCRT. 
Conclusion Although the addition of immunotherapy to SOC regimens did not result in a survival benefit, patients with HPV+ unresectable LA HNSCC may potentially derive benefit from immunotherapy.
DOI: 10.6084/m9.figshare.29069513.v1
title: Supplementary Material for: Additional immunotherapy to standard of care for unresectable locally advanced head and neck squamous cell carcinoma: a meta-analysis

description: Background The role of immunotherapy in the treatment of locally advanced head and neck squamous cell carcinoma (LA HNSCC) remains uncertain, particularly in cases of unresectable LA HNSCC. This meta-analysis aimed to evaluate the efficacy of immunotherapy in patients with unresectable LA HNSCC through a systematic review of the existing literature. 
Methods This meta-analysis followed a registered protocol on the INPLASY platform with the registration number INPLASY202510102. We systematically collected studies that compared the combination of immunotherapy and standard of care (SOC) with SOC alone for patients with unresectable LA HNSCC. Review Manager, Stata, and R software were employed to conduct single-group rate meta-analysis, pairwise meta-analysis, and Bayesian network meta-analysis. 
Results A meta-analysis of fifteen eligible studies involving 3,055 patients revealed no significant improvement in progression-free survival (PFS) or overall survival (OS) with the addition of immunotherapy. Specifically, in patients with human papilloma-positive (HPV+) LA HNSCC, the combination of pembrolizumab and concurrent chemoradiotherapy (CCRT) resulted in 2-year PFS and OS rates of 93% and 97%, respectively. In contrast, LA HNSCC patients treated with chemoradiotherapy followed by sequential pembrolizumab exhibited 2-year PFS and OS rates of 89% and 94%, respectively. Furthermore, our study demonstrated that the combination of pembrolizumab and CCRT achieved a higher 2-year PFS rate compared to the combination of avelumab and CCRT. 
Conclusion Although the addition of immunotherapy to SOC regimens did not result in a survival benefit, patients with HPV+ unresectable LA HNSCC may potentially derive benefit from immunotherapy.
DOI: 10.15468/dl.swgkqn
title: Occurrence Download

description: A dataset containing 2711 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is NYSDEC aerial surveys"
 ]
}

 The dataset includes 2711 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0032640-250426092105405/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.15412715
title: Unraveling the regulatory network of barley grain metabolism through the integrative analysis of multiomics and mQTL

description: This dataset contains raw data describing the co-expression regulatory network between metabolomics and transcriptomics in the study titled "Unraveling the regulatory network of barley grain metabolism through the integrative analysis of multiomics and mQTL". The dataset retains results meeting the thresholds of Pearson’s correlation coefficient (PPC) > 0.8 and p-value < 0.01.





Supplementary Data 2: Pearson's correlations between genes and annotated metabolites (PPC > 0.8, p < 0.01).




Supplementary Data 3: Pearson's correlations between genes and unknown metabolites (PPC > 0.8, p < 0.01).



Data Fields





Gene ID: Gene identifiers from the barley Morex v3 reference genome.




Peak number: Unique identifier for metabolites.




Compound: Name of the annotated metabolite (applies to Supplementary Data 2 only).




Class: Classification category of the metabolite.




Correlation_coefficient: Pearson’s correlation coefficient between metabolite abundance and gene expression levels.




pvalue: Results of the two-tailed t-test for null hypothesis testing.



The dataset provides a comprehensive resource for exploring gene-metabolite regulatory interactions in barley grain metabolism.
DOI: 10.5281/zenodo.15412716
title: Unraveling the regulatory network of barley grain metabolism through the integrative analysis of multiomics and mQTL

description: This dataset contains raw data describing the co-expression regulatory network between metabolomics and transcriptomics in the study titled "Unraveling the regulatory network of barley grain metabolism through the integrative analysis of multiomics and mQTL". The dataset retains results meeting the thresholds of Pearson’s correlation coefficient (PPC) > 0.8 and p-value < 0.01.





Supplementary Data 2: Pearson's correlations between genes and annotated metabolites (PPC > 0.8, p < 0.01).




Supplementary Data 3: Pearson's correlations between genes and unknown metabolites (PPC > 0.8, p < 0.01).



Data Fields





Gene ID: Gene identifiers from the barley Morex v3 reference genome.




Peak number: Unique identifier for metabolites.




Compound: Name of the annotated metabolite (applies to Supplementary Data 2 only).




Class: Classification category of the metabolite.




Correlation_coefficient: Pearson’s correlation coefficient between metabolite abundance and gene expression levels.




pvalue: Results of the two-tailed t-test for null hypothesis testing.



The dataset provides a comprehensive resource for exploring gene-metabolite regulatory interactions in barley grain metabolism.
DOI: 10.5281/zenodo.15422280
title: Unraveling the regulatory network of barley grain metabolism through the integrative analysis of multiomics and mQTL

description: This dataset contains raw data describing the co-expression regulatory network between metabolomics and transcriptomics in the study titled "Unraveling the regulatory network of barley grain metabolism through the integrative analysis of multiomics and mQTL". The dataset retains results meeting the thresholds of Pearson’s correlation coefficient (PPC) > 0.8 and p-value < 0.01.





Supplementary Data 2: Pearson's correlations between genes and annotated metabolites (PPC > 0.8, p < 0.01).




Supplementary Data 3: Pearson's correlations between genes and unknown metabolites (PPC > 0.8, p < 0.01).



Data Fields





Gene ID: Gene identifiers from the barley Morex v3 reference genome.




Peak number: Unique identifier for metabolites.




Compound: Name of the annotated metabolite (applies to Supplementary Data 2 only).




Class: Classification category of the metabolite.




Correlation_coefficient: Pearson’s correlation coefficient between metabolite abundance and gene expression levels.




pvalue: Results of the two-tailed t-test for null hypothesis testing.



The dataset provides a comprehensive resource for exploring gene-metabolite regulatory interactions in barley grain metabolism.
DOI: 10.15468/dl.z5ytwb
title: Occurrence Download

description: A dataset containing 243 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Saussurea sessiliflora (Koidz.) Kadota",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Country is Japan"
 ]
}

 The dataset includes 243 records from 18 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0032642-250426092105405/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.fgj9uy
title: Occurrence Download

description: A dataset containing 59 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Parnassia alpicola Makino",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Country is Japan"
 ]
}

 The dataset includes 59 records from 9 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0032643-250426092105405/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.5npejz
title: Occurrence Download

description: A dataset containing 1703779 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Continent is Asia",
 "Country is one of (China, Chinese Taipei)",
 "OccurrenceStatus is Present",
 "TaxonKey is Insecta"
 ]
}

 The dataset includes 1703779 records from 2031 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0032629-250426092105405/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.wzyvxv
title: Occurrence Download

description: A dataset containing 3 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Ipomoea batatas",
 "Country is Timor-Leste",
 "HasCoordinate is true"
 ]
}

 The dataset includes 3 records from 3 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0011664-250802193616735/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.pxhsp6
title: Occurrence Download

description: A dataset containing 4647 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Aegilops triuncialis",
 "Geometry POLYGON ((26.04335 1.226334, 135.0263 1.226334, 135.0263 55.38525, 26.04335 55.38525, 26.04335 1.226334))",
 "HasCoordinate is true"
 ]
}

 The dataset includes 4647 records from 73 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0011665-250802193616735/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.